Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Non-Hodgkin 13Lymphoma, B-Cell 10Lymphoma 10Lymphoma, Follicular 7Recurrence 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, Mantle-Cell 3Leukemia 3Burkitt Lymphoma 3Solid Tumors 2Neoplasms 2Melanoma 2Colorectal Neoplasms 2Bronchiolitis Obliterans Syndrome 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Cancers 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Mycosis Fungoides 1Mesothelioma 1Mature B-cell Malignancies 1Mature B-Cell Malignancies 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

palbociclib 2duvelisib 2berzosertib 2Fulvestrant 2Everolimus 2volagidemab 1serabelisib 1ribociclib 1pembrolizumab 1olaparib 1obinutuzumab 1lorlatinib 1gedatolisib 1encorafenib 1cobimetinib 1chiauranib 1capivasertib 1binimetinib 1Topotecan 1Radiotherapy 1Panobinostat 1PX-866 1NVP-BKM120 1Letrozole 1Cetuximab 1CYH33 1BAY 1895344 1AZD1390 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hereditary Sensory and Autonomic Neuropathies × obinutuzumab × Clear all
NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

SecuraBio

Phase 1 Terminated
3 enrolled
LymphoidOther hematologic neoplasm

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡